Literature DB >> 30506991

Human RNF113A participates of pre-mRNA splicing in vitro.

Guilherme H Gatti da Silva1, Melissa S Jurica2, Julia P Chagas da Cunha3, Carla C Oliveira4, Patricia P Coltri1,2,4.   

Abstract

Pre-messenger RNA (mRNA) splicing is an essential step in the control of eukaryotic gene expression. During splicing, the introns are removed from the gene transcripts as the exons are ligated to create mature mRNA sequences. Splicing is performed by the spliceosome, which is a macromolecular complex composed of five small nuclear RNAs (snRNAs) and more than 100 proteins. Except for the core snRNP proteins, most spliceosome proteins are transiently associated and presumably involved with the regulation of spliceosome activity. In this study, we explored the association and participation of the human protein RNF113A in splicing. The addition of excess recombinant RNF113A to in vitro splicing reactions results in splicing inhibition. In whole-cell lysates, RNF113A co-immunoprecipitated with U2, U4, and U6 snRNAs, which are components of the tri-snRNP, and with proteins PRP19 and BRR2. When HeLa cells were CRISPR-edited to reduce the RNF113A levels, the in vitro splicing efficiency was severely affected. Consistently, the splicing activity was partially restored after the addition of the recombinant GST-RNF113A. On the basis on these results, we propose a model in which RNF113A associates with the spliceosome by interacting with PRP19, promoting essential rearrangements that lead to splicing.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  RNF113A; ZNF183; pre-messenger RNA splicing; spliceosome

Year:  2018        PMID: 30506991     DOI: 10.1002/jcb.28163

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  2 in total

1.  Identification of Ku70 Domain-Specific Interactors Using BioID2.

Authors:  Sanna Abbasi; Caroline Schild-Poulter
Journal:  Cells       Date:  2021-03-14       Impact factor: 6.600

2.  Nonsense-Mediated RNA Decay Is a Unique Vulnerability of Cancer Cells Harboring SF3B1 or U2AF1 Mutations.

Authors:  Abigael Cheruiyot; Shan Li; Sridhar Nonavinkere Srivatsan; Tanzir Ahmed; Yuhao Chen; Delphine S Lemacon; Ying Li; Zheng Yang; Brian A Wadugu; Wayne A Warner; Shondra M Pruett-Miller; Esther A Obeng; Daniel C Link; Dalin He; Fei Xiao; Xiaowei Wang; Julie M Bailis; Matthew J Walter; Zhongsheng You
Journal:  Cancer Res       Date:  2021-07-02       Impact factor: 12.701

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.